Search

Your search keyword '"Kyrtsonis, Marie‐Christine"' showing total 65 results
Start Over Author "Kyrtsonis, Marie‐Christine" Database OpenAIRE
65 results on '"Kyrtsonis, Marie‐Christine"'

2. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Author

Vassilakopoulos, Theodoros P. Michail, Michail Papageorgiou, Sotirios Kourti, Georgia Angelopoulou, Maria K. Panitsas, Fotios Sachanas, Sotirios Kalpadakis, Christina Katodritou, Eirini Leonidopoulou, Theoni Kotsianidis, Ioannis and Hatzimichael, Eleftheria Kotsopoulou, Maria Dimou, Maria and Variamis, Eleni Boutsis, Dimitrios Terpos, Evangelos and Dimopoulou, Maria N. Karakatsanis, Stamatios Michalis, Eurydiki and Karianakis, George Tsirkinidis, Pantelis Vadikolia, Chryssa and Poziopoulos, Christos Pigaditou, Anna Vrakidou, Effimia and Economopoulos, Theophanis Kyriazopoulou, Lydia Siakantaris, Marina P. Kyrtsonis, Marie-Christine Symeonidis, Argyris and Anargyrou, Konstantinos Papaioannou, Maria Hatjiharissi, Evdoxia and Vervessou, Elissavet Tsirogianni, Maria Palassopoulou, Maria and Gainaru, Gabriella Stefanoudaki, Ekaterini Zikos, Panayiotis and Tsirigotis, Panayiotis Tsourouflis, Gerasimos and Assimakopoulou, Theodora Konstantinidou, Pavlina Papadaki, Helen A. Megalakaki, Katerina Dimopoulos, Meletios-Athanasios and Pappa, Vassiliki Karmiris, Themis Roussou, Paraskevi and Panayiotidis, Panayiotis Konstantopoulos, Kostas Pangalis, Gerassimos A.

Subjects
hemic and lymphatic diseases, Health Sciences, Επιστήμες Υγείας
Abstract

Background R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective but also more toxic than R-CHOP. Reliable prognostic classification is needed to guide treatment decisions. Materials and Methods We analyzed the impact of clinical prognostic factors on the outcome of 332 PMLBCL patients = 2 times upper limit of normal (model A) were significantly associated with FFP; E/IV and bulky disease (model B) were associated with LSS. Both models performed better than the International Prognostic Index (IPI) and the age-adjusted IPI by Harrel’s C rank parameter and Akaike information criterion. Both models A and B defined high-risk subgroups (13%-27% of patients [pts]) with approximately 19%-23% lymphoma-related mortality. They also defined subgroups composing approximately one-fourth or one-half of the patients, with 11% risk of failure and only 1% or 4% 5-year lymphoma-related mortality. Conclusion The combination of E/IV with either bulky disease or LDH >= 2 times upper limit of normal defined high-risk but not very-high-risk subgroups. More importantly, their absence defined subgroups comprising approximately one-fourth or one-half of the pts, with 11% risk of failure and minimal lymphoma-related mortality, who may not need more intensive treatment such as R-da-EPOCH. Implications for Practice By analyzing the impact of baseline clinical characteristics on outcomes of a large cohort of patients with primary mediastinal large B-cell lymphoma homogeneously treated with R-CHOP with or without radiotherapy, we developed novel prognostic indices which can aid in deciding which patients can be adequately treated with R-CHOP and do not need more intensive regimens such as R-da-EPOCH. The new indices consist of objectively determined characteristics (extranodal disease or stage IV, bulky disease, and markedly elevated serum lactate dehydrogenase), which are readily available from standard initial staging procedures and offer better discrimination compared with established risk scores (International Prognostic Index [IPI] and age-adjusted IPI).

Published
2021

4. Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Author

Kastritis, Eftathios Terpos, Evangelos Symeonidis, Argiris and Delimpasi, Sosana Cavo, Michele Zamagni, Elena Katodritou, Eirini Gamberi, Barbara Kyrtsonis, Marie-Christine and Gavriatopoulou, Maria Roussou, Maria Fotiou, Despina and Hatjiharissi, Evdoxia Kanellias, Nikolaos Migkou, Magdalini and Dimopoulos, Meletios A.

Published
2019

6. Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Author

Terpos, Evangelos Kastritis, Eftathios Hatjiharissi, Evdoxia and Katodritou, Eirini Eleutherakis-Papaiakovou, Evangelos Verrou, Evgenia Gavriatopoulou, Maria Leonidakis, Alexandros and Ntanasis-Stathopoulos, Ioannis Delimpasi, Sosana Kyrtsonis, Marie-Christine Papaioannou, Maria Symeonidis, Argiris and Dimopoulos, Meletios A.

Published
2019

7. Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group

Author

Katodritou, Eirini Kastritis, Efstathios Gatt, Moshe Cohen, Yael Avivi, Irit Pouli, Anastasia Lalayianni, Avgi Lavi, Noa Delimpasi, Sossana Kyrtsonis, Marie-Christine Michael, Michalis Suriu, Celia Miri, Zektser Tzarfati, Katrin Hertzog and Vadikolia, Chrysanthi Maltezas, Dimitrios Zikos, Panagiotis and Ganzel, Chezi Vaxman, Julia Aviv, Ariel Christoforidou, Anna Gavriatopoulou, Maria Shaulov, Adir Verrou, Evgenia

Published
2019

9. Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Author

Gavriatopoulou, Maria Kastritis, Efstathios and Ntanasis-Stathopoulos, Ioannis Kyrtsonis, Marie-Christine and Symeonidis, Argiris Hatjiharissi, Evdoxia Repousis, Panagiotis and Giannakoulas, Nikolaos Spanoudakis, Emmanouil G. Delibasi, Sossana Michali, Evridiki Michael, Michalis D. Vassou, Amalia Giannouli, Stavroula Iskas, Michail Kaiafa, Georgia and Tsirigotis, Panagiotis Pouli, Anastasia Vervessou, Elina and Christoulas, Dimitrios Katodritou, Eirini Terpos, Evangelos and Dimopoulos, Meletios A.

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2018

10. Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Author

Katodritou, Eirini Kastritis, Efstathios Gatt, Moshe E. and Cohen, Yael C. Avivi, Irit Pouli, Anastasia Lalayianni, Avgi and Lavi, Noa Delibasi, Sossana Kyrtsonis, Marie-Christine and Michael, Michalis D. Suriu, Celia Zektser, Miri Tzarfati, Katrin Herzog Vadikolia, Chrysanthi Maltezas, Dimitrios and Zikos, Panagiotis Ganzel, Chezi Vaxman, Iuliana Aviv, Ariel and Christoforidou, Anna Gavriatopoulou, Maria Shaulov, Adir and Verrou, Evgenia Papanota, Aristea-Maria Fakinos, Gabriel and Gkioka, Annita Ioanna Palaska, Vasiliki Triantafyllou, Theodora and Konstantinidou, Pavlina Anagnostopoulos, Achilles Terpos, Evangelos Dimopoulos, Meletios A.

Published
2018

12. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis

Author

Dimou, Maria Iliakis, Theodore Maltezas, Dimitrios Bitsani, Aikaterini Kalyva, Sotiria Koudouna, Aspasia Kotsanti, Sotiria Petsa, Panayiota Papaioannou, Paraskevi Kyrtsonis, Marie-Christine Panayiotidis, Panayiotis

Abstract

Background/Aim: Hematological malignancies are frequently complicated by secondary immunodeficiency (SID). Immunoglobulin replacement with intravenous gamma globulins (IVIg) reduces infection incidence, antibiotics’ need and hospitalization days in these patients. Facilitated subcutaneous immunoglobulin replacement (fSCIg) has been studied in primary immunodeficiency patients and is equally efficacious with several advantages (self-administration, same bioavailability, long infusion intervals, fewer adverse drug reactions). fSCIg has been less extensively studied in SID. We present our retrospective single-center data of fSCIg administration to hematological patients with SID, focusing on efficacy and safety issues. Patients and Methods: Overall, 33 hematological patients with hypogammaglobulinemia were treated with fSCIg according to ESMO 2015 guidelines, between mid-October 2015 and mid-January 2018 in our Department. Results: The infection rate was very low (18.1%). Shorter infusion intervals further reduced it. ADRs were rare (9%) and mild (grade 1). fSCIg managed to reduce the everyday nursery/hospital burden of our tertiary hospital. Conclusion: fSCIg compares favorably to IVIg replacement in SID patients.

Published
2018

13. Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Author

Tsonis, Ioannis Kanellias, Nikolaos Lazaris, Vasileios and Panayiotidis, Panayiotis Sotiropoulos, Damianos Vassilakopoulos, Theodoros Arapidou, Zoi Eleutherakis-Papaiakovou, Evangelos and Boutsis, Dimitrios Galanopoulos, Athanasios Kotsianidis, Ioannis and Kyrtsonis, Marie-Christine Leonidopoulou, Theoni Pangalis, Gerasimos Papaioannou, Maria Polychronopoulou, Sophia and Pontikoglou, Charalampos Poulakidas, Elias Poziopoulos, Christos and Repousis, Panagiotis Topalidou, Maria Vallianatou, Kalliopi and Vervessou, Elina Viniou, Nora-Athina Angelopoulou, Maria and Baltadakis, Ioannis Dimou, Maria Gavriilaki, Eleni Iliakis, Theodoros Symeonidis, Argiris Delibasi, Sossana and Papathanassiou, Maria Marinakis, Theodoros Tsirigotis, Panagiotis Charchalakis, Nikolaos Terpos, Evangelos Pagoni, Maria

Published
2018

15. Validation of Frailty Assessment in Multiple Myeloma (MM) Patients

Author

Nikolaou, Eftychia Papaioannou, Paraskevi Kotsanti, Sotiria and Petsa, Panayiota Maltezas, Dimitrios Tzenou, Tatiana and Iliakis, Theodoros Koulieris, Efstathios Dimou, Maria and Bitsani, Aikaterini Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine

Published
2017

16. Real-World data for the Treatment of Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone in 2nd Line (Legend Study): The Prognostic Significance of Biochemical Versus Clinical Relapse

Author

Katodritou, Eirini Delimpasi, Sossana Kyrtsonis, Marie Christine and Kyriakou, Despoina Symeonidis, Argiris Spanoudakis, Emmanouil Vassilopoulos, Georgios Anagnostopoulos, Achilles and Kioumi, Anna Zikos, Panagiotis Aktypi, Anthi Mpriasoulis, Evangelos Megalakaki, Aikaterini Kotsopoulou, Maria and Repousis, Panagiotis Adamopoulos, Ioannis Gogos, Dimitrios and Papa, Vassiliki Papadaki, Helen Terpos, Evangelos

Published
2017

18. A Revised Staging System for Waldenström’s Macroglobulinemia

Author

Gavriatopoulou, Maria Kastritis, Efstathios Kyrtsonis, Marie Christine Hatjiharissi, Evdoxia Katodritou, Eirini Repousis, Panagiotis Symeonidis, Argiris Michael, Michalis Pouli, Anastasia Giannakoulas, Nikolaos others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2017

20. Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents

Author

Katodritou, Eirini Terpos, Evangelos Delimpasi, Sossana and Kotsopoulou, Maria Michalis, Eurydiki Vadikolia, Chrysanthi and Kyrtsonis, Marie-Christine Symeonidis, Argiris Giannakoulas, Nikolaos Vadikolia, Chrissa Michael, Michalis Kalpadakis, Christina Gougopoulou, Theodora Prokopiou, Chrystalla and Kaiafa, Georgia D. Christoulas, Dimitrios Gavriatopoulou, Maria and Giannopoulou, Evlampia Lampropoulou, Vasiliki Verrou, Evgenia Kastritis, Efstathios Konstantinidou, Pavlina and Anagnostopoulos, Achilles Dimopoulos, Meletios A.

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2016

29. Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients

Author

Zomas, Athanasios Terpos, Evangelos Katodritou, Eirini and Symeonidis, Argiris Delimpasi, Sosana Pouli, Anastasia and Vassilakopoulos, Theodoros P. Michalis, Eurydiki Giannouli, Stavroula Kartasis, Zafiris Christoforidou, Anna Kokoviadou, Kiriaki Hatzimichael, Eleftheria Gika, Dimitra Megalakaki, Catherine Papaioannou, Maria Kyrtsonis, Marie-Christine and Konstantopoulos, Kostas Dimopoulos, Meletios A. Kastritis, Efstathios

Published
2014

31. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group

Author

Terpos, Evangelos Christoulas, Dimitrios Kastritis, Efstathios Katodritou, Eirini Papatheodorou, Athanasios Pouli, Anastasia Kyrtsonis, Marie-Christine Michalis, Eurydiki Papanikolaou, Xenophon Gkotzamanidou, Maria others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2014

32. New Insights into Monoclonal B-Cell Lymphocytosis

Author

Kalpadakis, Christina, Pangalis, Gerassimos A., Sachanas, Sotirios, Vassilakopoulos, Theodoros P., Kyriakaki, Stavroula, Korkolopoulou, Penelope, Koulieris, Efstathios, Moschogiannis, Maria, Yiakoumis, Xanthi, Tsirkinidis, Pantelis, Kyrtsonis, Marie-Christine, Levidou, Georgia, Papadaki, Helen A., Panayiotidis, Panayiotis, and Angelopoulou, Maria K.

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases, chemical and pharmacologic phenomena, bacterial infections and mycoses
Abstract

Monoclonal B-cell lymphocytosis (MBL) is a premalignant condition characterized by the presence of less than 5000/μL circulating clonal B cells in otherwise healthy individuals. Three subcategories have been identified according to the immunophenotypic features: CLL-like, CD5(+) atypical, and CD5(−) MBL. CLL-like MBL is by far the most frequent and best studied category and further divided in low-count [LC] and high-count [HC] MBL, based on a cutoff value of 500/μL clonal B cells. LC-MBL typically remains stable and probably does not represent a truly premalignant condition, but rather an age-related immune senescence. On the other hand, HC-MBL is closely related to CLL-Rai0, bearing similar immunogenetic profile, and is associated with an annual risk of progression to CLL requiring therapy at a rate of 1.1%. Currently there are no reproducible factors for evaluating the risk of progression to CLL. CD5(−) MBL is characterized by an immunophenotype consistent with marginal zone origin and displays many similarities with marginal zone lymphomas (MZL), mainly the splenic MZL. The cutoff value of 5000/μL clonal B cells cannot probably be applied in CD5(−) MBL, requiring a new definition to describe those cases.

Published
2014
Full Text
View/download PDF

33. Monoclonal Immunoglobulin

Author

Kyrtsonis, Marie-Christine, Koulieris, Efstathios, Bartzis, Vassiliki, Pessah, Ilias, Nikolaou, Eftychia, Karalis, Vassiliki, Maltezas, Dimitrios, Panayiotidis, Panayiotis, and Harding, Stephen J.

Published
2013
Full Text
View/download PDF

35. A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays

Author

Koulieris, Efstathios Sarris, Katerina Kafasi, Nikolitsa and Bartzis, Vassiliki Tzenou, Tatiana Maltezas, Dimitrios and Sachanas, Sotirios P. Efthymiou, Anna Mpitsanis, Katerina and Vardounioti, Ioanna Dimou, Maria Vassilakopoulos, Theodoros P. and Siakantaris, Marina Angelopoulou, Maria K. Tsaftaridis, Panagiotis Mparmparousis, Despoina Matsouka, Charis and Pangalis, Gerasimos Panayiotidis, Panayiotis Kyrtsonis, Marie-Christine

Published
2012

39. Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cll) Prognosis

Author

Sarris, Katerina Bartzis, Vassiliki Maltezas, Dimitris and Koulieris, Efstathios Tzenou, Tatiana Sachanas, Sotirios P. and Nikolaou, Eftychia Efthymiou, Anna Bitsani, Katerina Dimou, Maria Vassilakopoulos, Theodoros Siakantaris, Marina and Angelopoulou, Maria K. Kontopidou, Flora Tsaftaridis, Panagiotis and Kafasi, Nikolitsa Pangalis, Gerassimos A. Panayiotidis, Panayiotis Harding, Stephen Kyrtsonis, Marie-Christine

Published
2012

40. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years

Author

Kastritis, Efstathios Kyrtsonis, Marie-Christine Hatjiharissi, Evdoxia Symeonidis, Argiris Michalis, Eurydiki Repoussis, Panagiotis Tsatalas, Konstantinos Michael, Michael Sioni, Anastasia Kartasis, Zafiris Stefanoudaki, Ekaterini and Voulgarelis, Michael Delimpasi, Sosana Gavriatopoulou, Maria and Koulieris, Efstathios Gika, Dimitra Vervesou, Elissavet and Konstantopoulos, Konstantinos Kokkini, Garyfalia Zomas, Athanasios Roussou, Paraskevi Anagnostopoulos, Nikolaos and Economopoulos, Theofanis Terpos, Evangelos Zervas, Konstantinos and Dimopoulos, Meletios A. Greek Myeloma Study Grp

Abstract

The treatment of Waldenstrom’s macroglobulinemia (WM) has changed over the last decades, mainly because of the introduction of nucleoside analogues and of rituximab while novel agents such as bortezomib have been recently introduced. We performed an analysis to investigate whether the outcome of patients with WM has improved over the last years, compared to that of patients who started treatment before new drugs became widely available, especially as part of the frontline treatment. We analyzed 345 symptomatic patients with WM: 130 who initiated treatment before and 215 who started treatment after January 1, 2000. Patients who started treatment in the latter group were older and had more often elevated beta2-microglobulin but the other characteristics were similar between the two groups. Most patients who started treatment before January 1, 2000 were treated upfront with alkylating agent-based regimens and most patients who started treatment after January 1, 2000 received rituximab-based regimens as initial treatment. Objective response (63 and 59%, respectively) and median overall survival, OS, (106.5 months for Group A and is estimated at 94 months for Group B, P = 0.327) were similar. There was also no difference regarding OS or cause specific survival (CSS) in each risk group according to IPSSWM. Our observation may be explained by the indolent course of WM in several patients and by the lack of profound cytoreduction in patients with high-risk disease. Possible differences in the 15- or 20-year survival rate between the two groups may be detected with further follow-up of these patients. Am. J. Hematol. 86:479-483, 2011. (C) 2011 Wiley-Liss, Inc.

Published
2011

41. New gene functions in megakaryopoiesis and platelet formation

Author

Gieger, Christian Radhakrishnan, Aparna Cvejic, Ana Tang, Weihong Porcu, Eleonora Pistis, Giorgio Serbanovic-Canic, Jovana Elling, Ulrich Goodall, Alison H. Labrune, Yann and Lopez, Lorna M. Maegi, Reedik Meacham, Stuart Okada, Yukinori Pirastu, Nicola Sorice, Rossella Teumer, Alexander and Voss, Katrin Zhang, Weihua Ramirez-Solis, Ramiro Bis, Joshua C. Ellinghaus, David Goegele, Martin Hottenga, Jouke-Jan Langenberg, Claudia Kovacs, Peter O'Reilly, Paul F. Shin, So-Youn Esko, Toenu Hartiala, Jaana Kanoni, Stavroula Murgia, Federico Parsa, Afshin Stephens, Jonathan and van der Harst, Pim van der Schoot, C. Ellen Allayee, Hooman and Attwood, Antony Balkau, Beverley Bastardot, Francois and Basu, Saonli Baumeister, Sebastian E. Biino, Ginevra Bomba, Lorenzo Bonnefond, Amelie Cambien, Francois Chambers, John C. Cucca, Francesco D'Adamo, Pio Davies, Gail de Boer, Rudolf A. de Geus, Eco J. C. Doering, Angela Elliott, Paul and Erdmann, Jeanette Evans, David M. Falchi, Mario Feng, Wei Folsom, Aaron R. Frazer, Ian H. Gibson, Quince D. and Glazer, Nicole L. Hammond, Chris Hartikainen, Anna-Liisa and Heckbert, Susan R. Hengstenberg, Christian Hersch, Micha and Illig, Thomas Loos, Ruth J. F. Jolley, Jennifer Khaw, Kay Tee Kuehnel, Brigitte Kyrtsonis, Marie-Christine Lagou, Vasiliki Lloyd-Jones, Heather Lumley, Thomas Mangino, Massimo Maschio, Andrea Leach, Irene Mateo McKnight, Barbara and Memari, Yasin Mitchell, Braxton D. Montgomery, Grant W. and Nakamura, Yusuke Nauck, Matthias Navis, Gerjan Noethlings, Ute Nolte, Ilja M. Porteous, David J. Pouta, Anneli and Pramstaller, Peter P. Pullat, Janne Ring, Susan M. Rotter, Jerome I. Ruggiero, Daniela Ruokonen, Aimo Sala, Cinzia and Samani, Nilesh J. Sambrook, Jennifer Schlessinger, David and Schreiber, Stefan Schunkert, Heribert Scott, James Smith, Nicholas L. Snieder, Harold Starr, John M. Stumvoll, Michael and Takahashi, Atsushi Tang, W. H. Wilson Taylor, Kent and Tenesa, Albert Thein, Swee Lay Toenjes, Anke Uda, Manuela and Ulivi, Sheila van Veldhuisen, Dirk J. Visscher, Peter M. and Voelker, Uwe Wichmann, H-Erich Wiggins, Kerri L. Willemsen, Gonneke Yang, Tsun-Po Zhao, Jing Hua Zitting, Paavo and Bradley, John R. Dedoussis, George V. Gasparini, Paolo and Hazen, Stanley L. Metspalu, Andres Pirastu, Mario Shuldiner, Alan R. van Pelt, L. Joost Zwaginga, Jaap-Jan Boomsma, Dorret I. Deary, Ian J. Franke, Andre Froguel, Philippe and Ganesh, Santhi K. Jarvelin, Marjo-Riitta Martin, Nicholas G. and Meisinger, Christa Psaty, Bruce M. Spector, Timothy D. and Wareham, Nicholas J. Akkerman, Jan-Willem N. Ciullo, Marina and Deloukas, Panos Greinacher, Andreas Jupe, Steve Kamatani, Naoyuki Khadake, Jyoti Kooner, Jaspal S. Penninger, Josef and Prokopenko, Inga Stemple, Derek Toniolo, Daniela and Wernisch, Lorenz Sanna, Serena Hicks, Andrew A. Rendon, Augusto Ferreira, Manuel A. Ouwehand, Willem H. Soranzo, Nicole

Abstract

Platelets are the second most abundant cell type in blood and are essential for maintaining haemostasis. Their count and volume are tightly controlled within narrow physiological ranges, but there is only limited understanding of the molecular processes controlling both traits. Here we carried out a high-powered meta-analysis of genome-wide association studies (GWAS) in up to 66,867 individuals of European ancestry, followed by extensive biological and functional assessment. We identified 68 genomic loci reliably associated with platelet count and volume mapping to established and putative novel regulators of megakaryopoiesis and platelet formation. These genes show megakaryocyte-specific gene expression patterns and extensive network connectivity. Using gene silencing in Danio rerio and Drosophila melanogaster, we identified 11 of the genes as novel regulators of blood cell formation. Taken together, our findings advance understanding of novel gene functions controlling fate-determining events during megakaryopoiesis and platelet formation, providing a new example of successful translation of GWAS to function.

Published
2011

42. Prognostication of the High-Risk WM Patient

Author

Kastritis, Efstathios Gavriatopoulou, Maria Kyrtsonis, Marie-Christine Michael, Michael Hadjiharissi, Evdoxia Symeonidis, Argiris Michalis, Eurydiki Repoussis, Panagiotis Tsatalas, Konstantinos Sioni, Anastasia others

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Waldenstrom’s macroglobulinemia is characterized by a protracted course in most patients and the median survival may be long. However, a subset of patients may present with more aggressive disease that is associated with short survival. In order to better characterize these “poor-risk” patients, we identified patients who died within 2 years from the initiation of front-line treatment. These patients were older and had more often features of aggressive disease, such as elevated LDH and low serum albumin than the standard-risk population. Furthermore, only a minority of poor-risk patient had a response to initial therapy. However, conventional clinical factors or even the lack on response could not adequately identify poor-risk patients, indicating the need for novel molecular or other markers that would be able to effectively recognize patients at greatest need for aggressive therapies.

Published
2011

43. Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity

Author

Kyrtsonis, Marie Christine

Subjects
The Application of Clinical Genetics
Abstract

Marie-Christine Kyrtsonis1,2, Vassiliki Bartzis1,2, Xenophon Papanikolaou1, Efstathios Koulieris1,2, George Georgiou2, Maria Dimou2, Tatiana Tzenou1,2, Panayiotis Panayiotidis21First Department of Propedeutic Internal Medicine, 2Department of Hematology, National and Kapodistrian University of Athens, Laikon Hospital, GreeceAbstract: Multiple myeloma (MM) is a heterogeneous plasma cell neoplasm presenting with a wide range of clinical manifestations. In spite of the availability of very performing treatment modalities, survival is highly varying, ranging from a few months to several years. Underlying genetic and microenvironmental mechanisms are thought to be responsible for clinical heterogeneity. Disease etiology is unknown but progresses in the understanding of its pathogenesis have shown that MM precursor cell transformation into a malignant one occurs in a multistep process. Possibly during class switch recombination a primary genetic event takes place. With the occurrence of additional events and the support of bone marrow microenvironmental cells, neoplastic plasma cells actively proliferate and disease behavior may change. Recurrent translocations involving the IgH locus (11q13, 4p16, 16q23, 21q12, and 6p21), deletions of chromosome 13, trisomies of chromosomes 3, 5, 9, 11, 15, 19, and 21, and dysregulated expression of cyclin D genes, are considered initiating or primary events. Alterations related to further disease transformation and adverse prognosis are deletion of 17p13, c-myc translocations, and gains of chromosome 1q21. In relation to the underlying genetic defects, disease subgroups are recognized. Accordingly treatment effectiveness may differ among groups. Intense research is ongoing in this field.Keywords: myeloma, pathogenesis, genetic abnormalities, heterogeneity, prognosis

Published
2010

47. Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece

Author

Michael, Michael Kastritis, Efstathios Delimpassi, Sossana Michalis, Evridiki Repoussis, Panagiotis Kyrtsonis, Marie-Christine Katodritou, Eirini Anagnostopoulos, Nicolaos Zervas, Konstantinos Dimopoulos, Meletios A

Subjects
Health Sciences, Επιστήμες Υγείας
Abstract

Background: Primary systemic light-chain (AL) amyloidosis is characterized by the deposition of immunoglobulin light chain-derived amyloid fibrils in various tissues leading to multiorgan dysfunction. Patients and Methods: In order to define characteristics, treatment, and outcome of Greek patients with AL amyloidosis, we analyzed 112 unselected patients with AL from several hospitals. Results: The heart was involved in 59% of patients and kidneys in 71%. Patients were treated with several different treatment regimens; high-dose dexamethasone-based regimens were used as primary treatment in 43% and melphalan-based regimens in 37%, while 12% received up-front bortezomib with dexamethasone. A hematologic response to first-line therapy was documented in 50% (complete response, 14.5%), and organ responses were observed in 25% of patients, the latter being strongly associated with achievement of hematologic response. Median overall survival was 34.2 months and was independently affected by heart involvement, creatinine, age, involvement of >= 2 organs, and bone marrow plasmacytosis > 30%. In patients with cardiac involvement, advanced age and extended bone marrow plasmacytosis were associated with an even worse outcome, while for patients without heart involvement, only bone marrow plasmacytosis was independently associated with survival. Hematologic response was associated with improved survival in patients with heart involvement but mostly in patients with less bone marrow infiltration. Conclusion: In this first series of patients from Greece with AL amyloidosis, disease features and outcome appeared similar to those reported from tertiary centers. Heart involvement and bone marrow plasma cell infiltration comprise adverse prognostic factors but also indicate the heterogeneity of the disease and the need for individual treatment approaches.

Published
2010

48. Seminars in

Author

Dimopoulos, Meletios A Attal, Michel Kyrtsonis, Marie-Christine Maltezas, Dimitrios Tzenou, Tatiana Koulieris, Efstathios Bradwell, Arthur R Rajkumar, S Vincent Sonneveld, Pieter Harousseau, Jean-Luc others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2009

50. Seminars in

Author

Dimopoulos, Meletios A Attal, Michel Kyrtsonis, Marie-Christine Maltezas, Dimitrios Tzenou, Tatiana Koulieris, Efstathios Bradwell, Arthur R Rajkumar, S Vincent Sonneveld, Pieter Harousseau, Jean-Luc others

Subjects
Health Sciences, Επιστήμες Υγείας
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results